Merck, makers of Braveto, responds to the FDA's notification to pet owners and veterinarians about potential neurological effects in dogs and cats treated with flea and tick drugs containing isoxazoline. Here is their official company response and then below it is a link to a fact sheet for more information on the topic. “Merck Animal Health, the manufacturer of the Bravecto portfolio of products, remains confident in the safety and efficacy of Bravecto, which has been established through comprehensive clinical research in more than 170 studies. Nothing has changed about the Bravecto product. The current FDA communication is based on information gathered on the isoxazoline class as a whole and therefore applies to all products in the class, which includes Bravecto. After over three years of surveillance of more than 80 million Bravecto doses distributed in 85 countries, the overall worldwide reporting rate for neurological signs, including seizures, remains classified as very rare. Very rare is defined by international regulatory authorities as less than 1 in 10,000 reported adverse events. Every molecule is unique, even within a class, and each has its own safety profile. This is why it’s important for all pet owners to speak to their veterinarian before making a decision about flea and tick control products for their dog. Nothing is more important to Merck Animal Health than the safety and efficacy of our products and the well-being of animals. We encourage all pet owners to speak to their veterinarian before making a decision about flea and tick control products. More than just a nuisance, fleas and ticks transmit disease and pose animal and human health risks. It is critical to protect pets from these parasites.” Link to FDA Fact Sheet >
Our Employee of the Month for August is Luisa! Although she is often found out front, Luisa floats seamlessly from the front to the back as needed to be a DA or Concierge. She also has done a great job training our new CSRs, as well as managing our food orders. Having been with us for several years, she is also always a good resource for both clients and staff to tap for information. You never know where you will find Luisa each day, but no matter where she is, you know the job she is assigned will be done well and done on time. Thank you Luisa for all that you do for the hospital, your co-workers and our patients! Job well done!
In light of the recent “outbreak” of the H3N2 Canine Influenza, the Doctors at Bulls Head Pet Hospital now are recommending all “high risk” dogs (Dogs who attend doggy daycare, boarding facilities, grooming, frequent dog park visits, etc) to be vaccinated for the Canine Influenza. The product we believe is most effective contains both the H3N2 strain as well as the H3N8 strain. This vaccine is required to be administered in a series of 2 inoculations separated by 2-3 weeks. And then are annual from there. The cost of each vaccine is $49. Please let us know if you have further questions. As this is a very fluid situation we will keep our clientele abreast of any changes. Keep in mind, this most recent outbreak has been isolated to lower Manhattan and Brooklyn. There are tests for the Canine Influenza, please inquire with the staff if you have further inquiries. Read more: What Pet Owners Need to Know About Dog Flu (pdf)
Dr. Nolan Zeide Gives Dr. Brian Sheets a Tour of a Pet Exam on YouTube
Search Health Topics Useful Pet Links Fear Free
Meet Nolan Zeide of Bull's Head Pet Hospital An interview with Dr. Zeide is featured on parkbench.com. Read it here >